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Abstract 
Background: To isolate and analyze  drug 
sensitivity of Extended Spectrum Beta Lactamase 
(ESBL) Uropathogens 
Methods: A total number of 500 urine samples 
were processed. Out of these  250 were positive on 
culture.Antimicrobiol susceptibility testing was 
performed by Kirby Bauers disc diffusion method. 
Isolates resistant to third generation cephalosporins 
were tested for ESBL production by double disk 
synergy test method. An Oxide combination disc and 
the equivalent single Cephalosporin disc were 
placed on the plate. ESBL detection was carried out 
by a double disc diffusion method of Jarlieret al. 
Results: Escherichia coli  (34.0%) was the 
commonest, followed by  Klebsiella species (16%), 
Staphylococcus saprophyticus  (12.0%), Proteus  
(9.60%), Staphylococcus epidermidis (9.20%), 
Staphylococcus aureus (8.4%), Pseudomonas species 
 (7.20%), Enterobacter (2.0%) and Enterococci (1.6%). 
Out of all these, the two principal isolates which 
were ESBL producing organisms were E. Coli (20%) 
and Klebsiella species (30%). They also showed 
multidrug resistance to quinolone derivatives and 
third generation cephalosporin groups of 
drugs.There were total fifty (50) organisms which 
were ESBL producing isolates. 
Conclusion: The ESBL producing organisms are 
resistant to third generation cephalosporins and also 
other antibiotics like quinolone derivatives . 
Antibiotics of choice for infections by ESBL 
producing organisms are the carbapenems. 
Key Words: Extended spectrum beta 
lactamases(ESBL), Enterobacteraceae, E.coli. 
 
Introduction 
  The incidence of extended-spectrum beta 
lactamases(ESBL) varies worldwide. ESBLproducing 
organisms are resistant to third generation 
cephalosporins and many other  antibiotics like 
fluoroquinolones and cefepime. The pathogen of 
Enterobacteraceae family which harbours Extended 
Spectrum betalactamases (ESBLs) have caused 
numerous outbreaks of infection and it is becoming an 
increasing therapeutic problem not only in our country 
but all over the world.1 It has been observed that there 
is tremendous increase in the incidence of ESBL 
producing organisms of Enterobacteraceae family like 
Escherichia Coli and Klebsiella pneumonae, which 
results in limitation of therapeutic options.2 
The ESBL producing organisms are mostly gram 
negative organisms of Enterobacteracae family causing 
numerous outbreaks of infections. The incidence of 
ESBL producing strains among clinical isolates has 
been steadily increasing over the past years resulting 
in limitation of therapeutic options.¹ The prevalence of 
antibiotic resistance in bacteria isolated from patients 
is increasing. Most strains isolated from these 
infections are Escherichia coli, Klebsiella and 
Proteus.3Mutation within the structural genes 
encoding the older enzymes had occurred; giving rise 
to derivatives that possessed an extended substrate 
profile compared with that of parental enzymes. Thus 
these new enzymes give the name extended spectrum 
beta lactamases (ESBL) to reflect the fact that were 
derivatives of older enzymes and had a new capability 
to hydrolyse a broader spectrum of beta lactam drugs. 
Since the parental enzymes are sensitive to beta 
lactamase inhibitors, like clavulanic acid, the ESBLS 
are also sensitive to these inhibitors.4 
Over the last fifteen years multiple outbreaks of 
infection with ESBL producing organisms has been 
observed worldwide.² Microorganisms responsible for 
UTI such as E.coli, Klebsiella, Proteus and 
Enterobacter have the ability to produce ESBLs in 
large quantities. These enzymes are plasmid-borne 
and confer multiple drug resistance, making UTI 
difficult to treat.³ ESBL producing organisms are very 
difficult to eliminate because of their multi-drug 
resistance to various classes of antibiotics like third 
generation Cephalosporin,Monobactum, 
Carbapenems, Ciprofloxacin, Erythromycin and 
Betalactam, Betalactamase inhibitor combination.⁴,⁵ 
 
Materials And Methods 
This descriptive study was carried out in the Creek 
General Hospital (C.G.H), Karachi, during the period 
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of Feb 2014 to Feb 2015.A total number of 500 urine 
samples from out-patient department (OPD) of C.G.H 
were processed and organisms isolated in significant 
numbers were identified by standard methods.The 
specimens of urine were inoculated into blood agar, 
MacConkey’s agar and CLED (Cysteine-lactam 
Electrolytes Deficient) agar media and incubated at 
37O C aerobically. After overnight incubation, bacterial 
isolates were identified by colony morphology, 
staining, motility test and appropriate biochemical 
tests, like catalase, coagulase, oxidase and others. 
After performing the susceptibility test by using 
Mueller Hinton agar, an Oxide combination disc and 
the equivalent single Cephalosporin disc were placed 
on the plate i.e. ESBL detection was carried out by a 
double disc diffusion method of Jarlieret al.6 A 
susceptibility disc containing Augmentin was placed 
as the inhibitor of beta lactamase in the centre of the 
plate, and cefotaxime,ceftazidime, ceftriazone and 
aztreonam disc (30 µg each) were placed 30 mm 
(centre to centre) from the Co-amoxiclav disc (20/10 
µg ). Enhancement of the inhibition zone towards Co-
amoxicalv  disc indicating synergy of the calvulanic 
acid with anyone of the test antibiotics was taken as 
presumptive evidence of ESBL production. The quality 
control strains used for disc diffusion testing were 
E.coli ATCC 25922 and Klebsiella pneumoniae ATCC 
700603.Antibiotic discs of Co-amoxiclav (20/10ug), 
Ceftazidime(30ug),Cefotaxime(30ug),Ceftriaxone(30ug
) and ,Azactam(30ug).An organism was interpreted as 
containing an ESBL if there was an increase of ≥5 mm 
in the inhibition zone of the combination disc when 
compared to that of the cephalosporin alone 
Results 
During this study 500 patients were contacted who 
were complaining of symptoms of urinary tract 
infection. Out of these 250 were female and 250 male 
patients of the same age group.After taking complete 
history of urinary tract infection, 500 urine samples 
were processed in the laboratory for bacteriology and 
also for the detection of extended spectrum beta 
lactamases producing organisms of Enterobacteriaecae 
family like Escherichia coli and Klebsiella pneumonia. 
The positive culture recovered were 250 (50%), out of 
these 170 cultures belonged to the Enterobacteriaceae 
family, and a total of 50 cases (29.41%) of ESBL 
producing organisms were isolated (Table 1).The 
distribution of the 50 urinary isolates producing ESBL 
enzyme revealed 30% cases of E.coli,40% cases of 
Klebsiella, 16% cases of Proteus and 14% cases of 
Enterobacter (Table 2-4) . Antibiotic sensitivity pattern 
of ESBL producing organisms which belong to 
enterobacteriaceae family revealed that all the given 
members of enterobacteriaceae  family are more 
sensitive to carbapenem (IMP) group of drug, while 
they are less sensitive to third generation 
cephalosporin and C-amoxiclav too. Imipenem was 
the drug of choice for treating the ESBL producing 
organisms which especially belongs to 
enterobacteriaceae family of gram negative rods (Table 
5). 
Table 1:Distribution of ESBL producing Isolates 
in 500 specimens of urine. (n=500) 
Total No. 
of +ve 
organisms 
isolated 
% of 
+ve 
isolates 
Total No. of 
+ve 
organism of 
Enterobacter
iaceae 
family 
Total No. 
of 
ESBL 
producing 
organisms 
% of ESBL 
Producing 
organisms 
250 50% 170 50 29.411% 
 
Table 2:Distribution of urinary isolates 
producing ESBL in both sexes 
Organisms No. of ESBL 
producing 
isolates  
% of ESBL 
producing 
organisms 
E.coli 15 30.0% 
Klebsiellapneumoniae 20 40.0% 
Proteus 08 16.0% 
Enterobacter 07 14.0% 
 
Table 3:Distribution of ESBL producing 
organisms from the urine samples of female 
patients 
Organisms No. of ESBL 
producing 
isolates  
% of ESBL 
producing 
organisms 
E.coli 11 22.0% 
Klebsiellapneumoniae 12 24.0% 
Proteus 03 06.0% 
Enterobacter 05 10.0% 
 
Table 4:Distribution of ESBL Producing 
organisms from the urine samples of male 
patients 
Organisms No. of ESBL 
producing 
isolates  
% of ESBL 
producing 
organisms 
E.coli 04 8.0% 
Klebsiellapneumoniae 08 16.0% 
Proteus 05 10.0% 
Enterobacter 02 04.0% 
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Table 5: Antibiotic sensitivity pattern of ESBL 
producers (Total no. of ESBL producing organism = 50) 
No. & percentage 0f 
Organisms  
Cefo
taxi
me 
Ceft
azidi
me 
 
Ceftri
axone 
 
Azac
tam 
C-
amox
iclav 
Imi
pen
am 
1. E. coli 
ESBL Producer 
15 (30%) 
S 20% 15% 10% 30% 25% 98
% 
R 80% 85% 90% 70% 75% 02
% 
2. Klebsiella pneumonia 
ESBL Producer 
20 (40%) 
S 10% 17% 25% 05% 12% 95
% 
R 90% 83% 75% 95% 88% 05
% 
3. Proteus spp. 
ESBL Producer 
08 (16%) 
S 22% 20% 30% 11% 14% 99
% 
R 78% 80% 70% 89% 86% 01
% 
4. Enterobacter 
ESBL Producer 
07 (14%) 
S 16% 18% 20% 24% 28% 94
% 
R 84% 82% 80% 76% 72% 06
% 
Key words:R= Resistant;S= sensitive 
 
Discussion 
The occurrence of ESBL producing organisms has been 
increasing day by day throughout the world.7 The 
prevalence of ESBLs among clinical isolates varies 
greatly world-wide and pattern are rapidly changing 
over time.8The extended spectrum beta lactamase 
(ESBL) are the enzymes which are the derivatives of 
the old enzymes i.e., beta lactamase. These new 
enzymes (ESBL) developed resistance and have the 
capability to hydrolyse the broad spectrum third 
generation Cephalosporins like Cefotaxime, 
Ceftazidime and Ceftriaxone. A study from India by 
K.L. Shobha et.al showed 32% E.coli, and 37% of 
Klebsiella species  were found to be ESBL positive.9  In 
present study 30% E.Coli and 40 % Klebsiella species  
were found to be ESBL positive. Hence present study 
correlates with the study performed by K.L Shobha. 
On the other hand our study showed a higher 
percentage of ESBL producers when compared to the 
study by Jones et al.10Test performed for E.coli and 
Klebsiella species, antibiotic sensitivity shows lowest 
sensitivity to Norfloxcacin, Naladixic acid and highest 
sensitivity to Imipenem (100%). These findings also 
correlate with the studies conducted by Hansotiaet.al, 
Abigalet. Al and others.11-13 
The high prevalence rate of ESBL producing strain 
shave been reported in Klebsiella species, as  25.6%. In 
our study there are 20(40%)Klebsiella isolates  which 
were extended spectrum beta lactamase producer, 
While E. coli as ESBL producing organism has been 
reported by Supriya et al. which vary from 21- 34%.14 
In our study, E.coli ESBL producers are 30%, hence 
our study correlates with the study of Supriya et al.14In 
another study from India Khurrana et al.15 shows that 
ESBLproducing organism E.coli 24.7% whereas 
Klebsiella Speciecs are 38.5%, where as in our study 
E.coli as ESBL producer are 30% while Klebsiella 
species are 40%, which correlates with their study.15 
The risk factors which are associated with ESBL 
colonization infection are prolonged episodes of  
hospitalization and stay in ICU department,  severity 
of illness, previous exposure to antibiotic therapy like 
ceftazidime, cefotaxime, and aminoglycoside, urinary 
catheters, arterial catheterization, gut colonization, 
gastrostomy or jejunosotomy tube, ventilator 
dependence, emergency abdominal surgery and 
nasogastric intubation.The study also showed that 
ESBL production was high among uropathogens in 
female patients. The situation got worsened when 
there was increased multidrug resistance seen in ESBL 
producers as compared to those in non ESBL 
producers. Hence sensitive ESBL testing for 
uropathogens along with conventional antibiogram 
would be useful for all cases of urinary tract infection.  
 
Conclusion 
1.ESBL producing organisms are resistant to all the 
third generation cephalosporins and other antibiotics 
but only sensitive to Imipenem. 
2. Antibiotic resistance is becoming a big problem for 
the public health which threaten the lives of 
hospitalized persons as well as those with chronic 
illness. It also increases the health cost . 
3.Physicians must cater for the risk factors which can 
lead to the production of ESBL colonization  
4. It is required to formulate and then strictly follow 
antibiotic prescription policy 
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